Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)
Kindred Biosciences (NASDAQ: KIN) and Pain Therapeutics (NASDAQ:PTIE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Earnings and Valuation
This table compares Kindred Biosciences and Pain Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Kindred Biosciences||N/A||N/A||-$24.99 million||($1.17)||-6.84|
|Pain Therapeutics||N/A||N/A||-$12.95 million||($2.04)||-2.06|
Kindred Biosciences is trading at a lower price-to-earnings ratio than Pain Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
60.4% of Kindred Biosciences shares are held by institutional investors. Comparatively, 36.7% of Pain Therapeutics shares are held by institutional investors. 19.1% of Kindred Biosciences shares are held by company insiders. Comparatively, 32.7% of Pain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Kindred Biosciences and Pain Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Kindred Biosciences has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Pain Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Kindred Biosciences and Pain Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kindred Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 12.50%. Given Kindred Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Kindred Biosciences is more favorable than Pain Therapeutics.
Kindred Biosciences beats Pain Therapeutics on 8 of the 11 factors compared between the two stocks.
About Kindred Biosciences
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
About Pain Therapeutics
Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.